Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.
Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A. Di Veroli A, et al. Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. Leuk Res. 2018. PMID: 29625320 No abstract available.
Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy.
Sarlo C, Buccisano F, Maurillo L, Cefalo M, Di Caprio L, Cicconi L, Ditto C, Ottaviani L, Di Veroli A, Del Principe MI, Grasso MA, Nasso D, De Santis G, Amadori S, Venditti A. Sarlo C, et al. Among authors: di caprio l, di veroli a. Leuk Res Treatment. 2013;2013:705714. doi: 10.1155/2013/705714. Epub 2013 Apr 28. Leuk Res Treatment. 2013. PMID: 23738080 Free PMC article.
Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia.
Del Principe MI, Buccisano F, Maurillo L, Venditti D, Cefalo M, Sarlo C, Di Caprio L, Di Veroli A, Nasso D, Ceresoli E, Postorino M, Di Piazza F, Colandrea G, Conti F, Del Poeta G, Amadori S, Venditti A. Del Principe MI, et al. Among authors: di piazza f, di caprio l, di veroli a. Thromb Res. 2013 Nov;132(5):511-4. doi: 10.1016/j.thromres.2013.08.007. Epub 2013 Aug 16. Thromb Res. 2013. PMID: 24090605
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G. Latagliata R, et al. Among authors: di veroli a. Eur J Haematol. 2016 Jun;96(6):643-9. doi: 10.1111/ejh.12674. Epub 2015 Sep 18. Eur J Haematol. 2016. PMID: 26277477
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F. Andriani A, et al. Among authors: di veroli a. Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269. Am J Hematol. 2016. PMID: 26748894 Free article.
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R. Breccia M, et al. Among authors: di veroli a. Ann Hematol. 2017 Mar;96(3):387-391. doi: 10.1007/s00277-016-2884-7. Epub 2016 Nov 26. Ann Hematol. 2017. PMID: 27889820
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
Santoro C, Sperduti I, Latagliata R, Baldacci E, Anaclerico B, Avvisati G, Breccia M, Buccisano F, Cedrone M, Cimino G, De Gregoris C, De Muro M, Di Veroli A, Leonetti Crescenzi S, Montanaro M, Montefusco E, Porrini R, Rago A, Spadea A, Spirito F, Villivà N, Andriani A, Alimena G, Mazzucconi MG. Santoro C, et al. Among authors: di veroli a. Cancer Med. 2017 Jun;6(6):1233-1239. doi: 10.1002/cam4.1081. Epub 2017 May 23. Cancer Med. 2017. PMID: 28544749 Free PMC article.
High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia.
Latagliata R, Montanaro M, Cedrone M, Di Veroli A, Spirito F, Santoro C, Leonetti Crescenzi S, Porrini R, Di Giandomenico J, Villivà N, Spadea A, Rago A, De Gregoris C, Romano A, Anaclerico B, De Muro M, Felici S, Breccia M, Montefusco E, Bagnato A, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A; Gruppo Laziale, SMPC Ph1. Latagliata R, et al. Among authors: di giandomenico j, di veroli a. Thromb Res. 2017 Aug;156:168-171. doi: 10.1016/j.thromres.2017.06.023. Epub 2017 Jun 21. Thromb Res. 2017. PMID: 28662484
71 results